Paper
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
External resource. Not made or verified by Public Protocol.
NEJM 2025 report of a customised base-editing therapy for one infant with CPS1 deficiency; the authors state longer follow-up is needed.
https://doi.org/10.1056/NEJMoa2504747
- Maintainer
- Musunuru and colleagues
- Licence, as stated at its source
- Not stated on the page opened
- Open or commercial
- Not stated by the maker
- Maturity
- PrototypeOur reading, 16 November 2026
- Safety
- S3medical
- Review
- Listed 16 November 2026by Public Protocol editors
- Checked
- 16 November 2026
- Next check due
- 16 May 2027
- Steward
- Public Protocol editors
Where it sits in the blueprint
- Domains
- Stages
Learn
- Elements it supports
Recorded when its maker or a reviewer places it against single elements.
- Context
Climate, setting, scale, cost and skill: not stated in this entry. Check the source against your own place and numbers.
Verification
No verification is recorded on Public Platform for this entry. Records are added when someone reads it for accuracy, reviews it with a stated qualification, builds it or measures it.
Record
- How it came in
Seed catalogue, 16 November 2026. Listed from Praecise open research. The source was opened and described on the date shown.
- Licence
Not stated on the page opened. Read at https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:40373211%20AND%20SRC:MED&resultType=core&format=json. How licences are recorded
- Something wrong?